Gujarat Kidney Super Speciality Ltd vs Syngene International Ltd Stock Comparison
Gujarat Kidney Super Speciality Ltd vs Syngene International Ltd Stock Comparison
Last Updated on: Oct 31, 2026
Key Highlights
The Latest Trading Price of Gujarat Kidney & Super Speciality Ltd is ₹ 163.5 as of 30 Oct 15:30
. The P/E Ratio of Gujarat Kidney & Super Speciality Ltd changed from 51.4 on March 2026 to 51.4 on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Syngene International Ltd changed from 53.7 on March 2021 to 49.7 on March 2026 . This represents a CAGR of -1.28% over 6 years The Market Cap of Gujarat Kidney & Super Speciality Ltd changed from ₹ 798.29 crore on March 2026 to ₹ 798.29 crore on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Syngene International Ltd changed from ₹ 21734 crore on March 2021 to ₹ 15724 crore on March 2026 . This represents a CAGR of -5.25% over 6 years The revenue of Gujarat Kidney & Super Speciality Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 34.98 crore. This represent the decline of -100% The revenue of Syngene International Ltd for the Sep '26 is ₹ 860.7 crore as compare to the Jun '26 revenue of ₹ 761.3 crore. This represent the growth of 13.06% The ebitda of Gujarat Kidney & Super Speciality Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ 9.07 crore. This represent the decline of -100% The ebitda of Syngene International Ltd for the Sep '26 is ₹ 168.7 crore as compare to the Jun '26 ebitda of ₹ 102.6 crore. This represent the growth of 64.42% The net profit of Gujarat Kidney & Super Speciality Ltd changed from ₹ 2.96 crore to ₹ 0 crore over 10 quarters. This represents a CAGR of -100.00%
The net profit of Syngene International Ltd changed from ₹ 75.7 crore to ₹ 32.2 crore over 10 quarters. This represents a CAGR of -28.96%
The Dividend Payout of Gujarat Kidney & Super Speciality Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Syngene International Ltd changed from 10.18 % on March 2022 to 16.52 % on March 2026 . This represents a CAGR of 10.17% over 5 years .
About Gujarat Kidney & Super Speciality Ltd
Gujarat Kidney And Super Speciality Limited was incorporated under the name and style of Vihaan Medicare Private Limited', a private limited company, dated December 20, 2019 issued by the Registrar of Companies, Central Registration Centre.
Subsequently, the Company name was changed to Gujarat Kidney and Super Speciality Private Limited' and a fresh certificate of incorporation dated September 13, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad.
Further, Company' status was changed to a public limited company and the name of Company was changed to Gujarat Kidney and Super Speciality Limited' dated November 24, 2023 by the ROCs, Ahmedabad.
The Company operate a chain of mid-sized multispecialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care.
About Syngene International Ltd
Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.
Headquartered in India, the operations are driven by its highly qualified teams comprising 5641 scientists and its state-of-the-art facilities, spread over 2.5 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore.
The Company operate into 4 business divisions comprising of Discovery Services, Development Services, Manufacturing Services and the Dedicated Centers.
Syngene International Limited was incorporated at Bangalore in 1993.
The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited.
The Company's health-related services extend across all major therapeutic areas and modalities.
FAQs for the comparison of Gujarat Kidney & Super Speciality Ltd and Syngene International Ltd
Which company has a larger market capitalization, Gujarat Kidney & Super Speciality Ltd or Syngene International Ltd?
Market cap of Gujarat Kidney & Super Speciality Ltd is 1,289 Cr while Market cap of Syngene International Ltd is 16,251 Cr
What are the key factors driving the stock performance of Gujarat Kidney & Super Speciality Ltd and Syngene International Ltd?
The stock performance of Gujarat Kidney & Super Speciality Ltd and Syngene International Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Gujarat Kidney & Super Speciality Ltd and Syngene International Ltd?
As of October 31, 2026, the Gujarat Kidney & Super Speciality Ltd stock price is INR ₹163.5. On the other hand, Syngene International Ltd stock price is INR ₹402.6.
How do dividend payouts of Gujarat Kidney & Super Speciality Ltd and Syngene International Ltd compare?
To compare the dividend payouts of Gujarat Kidney & Super Speciality Ltd and Syngene International Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.